
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 21, 2018

AXOGEN, INC.

(Exact name of registrant as specified in its charter)

<hr/> Minnesota <hr/> <p>(State or other jurisdiction of incorporation)</p>	<hr/> 001-36046 <hr/> <p>(Commission File Number)</p>	<hr/> 41-1301878 <hr/> <p>(IRS Employer Identification No.)</p>
<hr/> 13631 Progress Boulevard, Suite 400, Alachua, Florida <hr/> <p>(Address of Principal Executive Offices)</p>		<hr/> 32615 <hr/> <p>(Zip Code)</p>

(386) 462-6800

Registrant's telephone number, including area code

(Former name or former address if changed since last report,)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 21, 2018, Lisa N. Colleran resigned as a member of the Board of Directors (the “Board”) of AxoGen, Inc. (the “Company”), and all committees of the Board on which she served effective immediately. Ms. Colleran conveyed to us that an unexpected opportunity to once again run a company presented itself and the time required by this new position made it necessary for her to reduce her other commitments. Ms.

Colleran’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 23, 2018

AXOGEN, INC.

By: /s/ Greg Freitag

Name: Greg Freitag

Title: General Counsel